 | • レポートコード：B-MOR-05190 • 出版社/出版日：Mordor Intelligence / 2018年3月 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：Healthcare |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、エリスロポエチン刺激剤の世界市場について調べ、エリスロポエチン刺激剤の世界規模、市場動向、市場環境、タイプ別分析、用途別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・エリスロポエチン刺激剤の世界市場インサイト ・エリスロポエチン刺激剤の世界市場環境 ・エリスロポエチン刺激剤の世界市場動向 ・エリスロポエチン刺激剤の世界市場規模 ・エリスロポエチン刺激剤の世界市場規模：タイプ別 ・エリスロポエチン刺激剤の世界市場規模：用途別 ・エリスロポエチン刺激剤の世界市場：地域別市場規模・分析 ・エリスロポエチン刺激剤の北米市場規模・予測 ・エリスロポエチン刺激剤のアメリカ市場規模・予測 ・エリスロポエチン刺激剤のヨーロッパ市場規模・予測 ・エリスロポエチン刺激剤のアジア市場規模・予測 ・エリスロポエチン刺激剤の日本市場規模・予測 ・エリスロポエチン刺激剤の中国市場規模・予測 ・エリスロポエチン刺激剤のインド市場規模・予測 ・エリスロポエチン刺激剤の韓国市場規模・予測 ・関連企業情報・競争状況 |
The global erythropoietin stimulating agents market is estimated to grow at a CAGR of about 8.3% during the forecast period. Erythropoietin stimulating agents are the drugs which are similar to erythropoietin. This agent stimulates the growth of red blood cells (RBC). Erythropoietin-stimulating agents are approved for the treatment of anemia due to chronic kidney failure (CKD), chemotherapy, HIV, and also for the reduced RBC during critical surgical procedures.
Increasing Incidence and Prevalence of Anemia
Over the past decade, anemia has emerged as one of the serious diseases related to nutrition, accompanied by increased morbidity and mortality. In major developing countries, neonatal and maternal mortality accounted for 3.0 million deaths, in 2013, and are important contributors to global mortality. Furthermore, about 90,000 deaths have been estimated in all genders and age groups, due to iron anemic deficiency. In 2013, WHO estimated that pregnant women (38%), non-pregnant women (29%), children (43%), and women of reproductive age (29%) suffer from anemia, corresponding to 496 million non-pregnant women, 273 million children and 32 million pregnant women, across the world. And even the chronic infections, including tuberculosis, malaria, HIV, and cancer can also lower blood Hb concentrations. All the above factors, like increased mortality, iron deficiency, and insufficient RBC production, are the major factors driving the erythropoietin stimulating agents market. The other factors, like increasing applications in HIV, end-stage renal disorder, and the risks of thrombosis during surgery and pure red cell aplasia, are driving the market.
Stringent Regulatory Scenario
Erythropoietin (EPO) has to be produced in mammalian cells, as microbes, such as bacteria and yeast, do not have the required cellular machinery. Due to the cell complexity, clinical investigation biologics involve special considerations. In the United States, biologics are approved under Public Health Service Act (PHSA), under which, originator biologics receive approval through 351(a) pathway (Biologics License Application (BLA)). The other factors, such as the continuous need of wireless communication mode and emerging economies, are restraining the market growth. Even approval of biosimilar EPO requires 351(k) pathway, for which, reference biologic is already approved through a BLA or the 351(a) pathway. The United States has adopted a regulatory process for biologics and biosimilars from Europe. Furthermore, a stringent regulatory scenario exists in developing countries as well. These strict regulatory guidelines are hindering the erythropoietin agents market. The other factor that is also restraining the market growth is the adverse effects of the erythropoietin agents.
Asia-Pacific is expected to grow at the Highest CAGR
Asia-Pacific region is expected to grow at the highest CAGR, during the forecast period. Because of the emerging economies and new product launches with better efficacy, it will be a big opportunity for the erythropoietin stimulating agents market.
North America region holds the largest market share, followed by Europe, in the forecast period.
Key Developments in the Market
• June 2017: Johnson & Johnson completed the acquisition of Actelion.
• January 2017: Amgen made an agreement with DaVita, for new sourcing and supply.
Major Players: 3SBIO INC., AMGEN, HOFFMANN LA ROCHE, JOHNSON & JOHNSON, BIOSIDUS, BIOCON, HOSPIRA, INTAS PHARMACEUTICALS, CELLTRION, and TEVA PHARMACEUTICALS INDUSTRIES, amongst others
Reasons to Purchase the Report
• Current and future market outlook for erythropoietin stimulating agents, in the developed and emerging markets
• Analyze various perspectives of the market, with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth, during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3-month analyst support, along with the market estimate sheet (in excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Incidence and Prevalence of Anemia
6.1.2 Applications in HIV and End-stage Renal Disorder
6.1.3 Risks of Thrombosis during Surgery and Pure Red Cell Aplasia
6.2 Market Restraints
6.2.1 Stringent Regulatory Guidelines
6.2.2 Adverse Side Effects
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 Segmentation -by Type
7.1.1 Epoetin – Alfa
7.1.2 Epoetin – Beta
7.1.3 Epoetin – Omega
7.1.4 Epoetin – Delta
7.1.5 Darbepoetin – Alpha
7.1.6 Others
7.2 Segmentation -by Application
7.2.1 Cancer Chemotherapy
7.2.2 Renal Disorders
7.2.3 Anti-retroviral treatment
7.2.4 Neural diseases
7.2.5 Others
7.3 Segmentation – by Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia
7.3.3.5 New Zealand
7.3.3.6 South Korea
7.3.3.7 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 3SBio Inc.
9.2 Amgen
9.3 Hoffmann La Roche
9.4 Johnson & Johnson
9.5 BioSidus
9.6 Biocon
9.7 Pfizer
9.8 Intas Pharmaceuticals
9.9 Celltrion
9.10 Teva Pharmaceuticals Industries
9.11 Others
10. Future of the Market